A summary of key peptides that undergo substantial changes in phosphorylation in response to a shift to poor carbon during mitosis
| Cellular Process . | Site Position . | Sequence . | A-score . | # of peptides . | Log2(Poor/Rich) . |
|---|---|---|---|---|---|
| MEN | |||||
| NET1 | |||||
| 212 | VST#PLAR | 0 | 3 | −4.497 | |
| 259 | ISS#GIDAGK | 24.43 | 6 | −4.409 | |
| 280 | S#ATVDPDK | 30.83 | 2 | −4.343 | |
| 362 | ITS#GM*LK | 24.43 | 3 | −4.259 | |
| 388 | EGPSSPAS#ILPAK | 5.08 | 3 | −3.419 | |
| 270 | SS#IVEEDIVSR | 9.34 | 1 | −3.180 | |
| 447 | S#QSSIADNNGS#PVK | 100.02 | 3 | −3.059 | |
| 301;304 | LLSGT#PIM*STMT#PNR | 4.08 | 3 | −2.740 | |
| 166 | LNNGS#PQSVQPQQQIPSSSGVLR | 15.01 | 2 | −1.640 | |
| 1164 | S#ASAALGK | 30.83 | 2 | −1.331 | |
| 48 | TNM*AQSAGDAS#LQYANLR | 33.66 | 2 | −1.315 | |
| CDC14 | |||||
| 537 | RTTS#AAGGIR | 6.59 | 1 | −2.903 | |
| 494;497 | KNDISS#ASS#SR | 17.01;9.34 | 1 | −1.590 | |
| 429 | SSAVPQTS#PGQPR | 30.83 | 5 | −1.533 | |
| LTE1 | |||||
| 789;793 | VQS#IAIT#PTK | 110.63 | 3 | −2.413 | |
| 718 | ST#IDGLEK | 24.44 | 1 | −2.220 | |
| 779 | QAVVRPAS#GR | 1000 | 1 | −1.857 | |
| 799 | ELS#IVDPEQNK | 1000 | 2 | −1.481 | |
| CDC15 | |||||
| 940 | VSSVT#AAIGSS#PTK | 2.81 | 1 | −1.668 | |
| BFA1 | |||||
| 317 | HCS#NQNVQLNGPAK | 1000 | 1 | −1.614 | |
| NUD1 | |||||
| 352 | APS#ILDK | 1000 | 1 | −1.469 | |
| TORC2 Signaling | |||||
| AVO2 | |||||
| 305 | VNS#INVK | 1000 | 1 | −3.872 | |
| 273 | SS#ITNPVFNPR | 17.01 | 2 | −2.293 | |
| 330;333 | HSAT#PTS#PHNNIALINR | 4.08;6.59 | 1 | −2.061 | |
| 310 | T#PVGVS#PK | 1000 | 1 | −1.432 | |
| 310;315 | T#PVGVS#PK | 1000;1000 | 2 | −1.387 | |
| TAP42 | |||||
| 251;260 | ESNDDDS#TGFT#DK | 85.26;13.38 | 1 | −3.872 | |
| GIN4 | |||||
| 471 | RAS#VINVEK | 1000 | 3 | −3.100 | |
| 382;389 | RQS#ISSVS#VSPSK | 20.17 | 1 | −2.569 | |
| 805 | HFS#ESNK | 30.83 | 2 | −2.338 | |
| 639 | SIS#APM*ENEEK | 0 | 1 | −1.648 | |
| 384 | RQS#IS#SVSVSPSK | 13.21 | 1 | −1.594 | |
| YPK1 | |||||
| 57 | GT#INPSNSSVVPVR | 59.30 | 5 | −2.807 | |
| 57;64 | GT#INPS#NSSVVPVR | 59.30;17.01 | 4 | −2.017 | |
| HSL1 | |||||
| 899 | NIS#QPVNSK | 9.30 | 1 | −2.790 | |
| 1210 | ETT#EEILSK | 9.34 | 2 | −2.082 | |
| 641 | AIHAS#PSTK | 33.66 | 1 | −1.893 | |
| 629;631;632 | SPS#RY#S#LSR | 30.83;24.24;17.01 | 1 | −1.848 | |
| BIT61 | |||||
| 164 | AS#GFFNR | 1000 | 1 | −2.721 | |
| TSC11 | |||||
| 19 | S#VTNTTPLLTPR | 48.87 | 1 | −2.372 | |
| 24;28 | SVTNT#TPLLT#PR | 9.34;65.44 | 1 | −2.176 | |
| 50;52 | NITSSS#PS#TITNESSK | 24.43;9.34 | 1 | −1.936 | |
| 251 | NSQQNLNRNS#TVNSR | 6.59 | 1 | −1.742 | |
| 19;28;32 | S#VTNTTPLLT#PRHS#R | 48.87;65.44;63.08 | 1 | −1.586 | |
| AVO1 | |||||
| 537 | DTVIS#GK | 33.66 | 1 | −2.332 | |
| 543 | EPTS#LTSSNR | 9.34 | 2 | −1.872 | |
| 588 | VSDS#VLHR | 6.59 | 3 | −1.704 | |
| 326 | SHFPTS#QK | 0 | 1 | −1.632 | |
| MSS4 | |||||
| 341 | RSES#ATAEIK | 20.17 | 3 | −2.039 | |
| 238 | HS#QILPM*DDSDVIK | 88.82 | 2 | −2.025 | |
| PKH2 | |||||
| 1005 | THSQS#PSIS#K | 11.01 | 4 | −1.585 | |
| PRK1 | |||||
| 488 | LS#PTIT#SK | 30.83 | 1 | −1.506 | |
| SLM2 | |||||
| 7;11 | NS#ARAS#LDLR | 1000;1000 | 1 | −1.466 | |
| Secretory Pathway | |||||
| SEC16 | |||||
| 1961 | AS#TNQYR | 24.44 | 2 | −3.849 | |
| 759 | GVS#NAS#VGSSASFGAR | 62.66 | 3 | −3.163 | |
| 2144 | TSPSPTGPNPNNSPSPS#S#PISR | 13.38 | 3 | −2.022 | |
| 759;762 | GVS#NAS#VGSSASFGAR | 62.66; 87.26 | 5 | −1.992 | |
| 806 | YAPVS#PTVQQK | 6.59 | 5 | −1.882 | |
| 766;768 | GVSNASVGSS#AS#FGAR | 4.08; 17.01 | 1 | −1.407 | |
| SEC31 | |||||
| 980 | APSS#VSM*VS#PPPLHK | 71.34 | 1 | −1.611 | |
| 988;992 | NS#RVPS#LVATSESPR | 113.18; 99.28 | 6 | −1.514 | |
| 988 | NS#RVPS#LVAT#SESPR | 113.18 | 3 | −1.475 | |
| Ribosome Biogenesis | |||||
| DOT6 | |||||
| 322;326;331 | RSS#FNVS#SNNT#SR | 24.44; 0; 9.34 | 1 | −4.104 | |
| 322 | RSS#FNVSSNNTSR | 24.44 | 2 | −3.133 | |
| 247 | SNS#HSFTNSLNQDPIVR | 11.01 | 2 | −1.687 | |
| 322;331 | RSS#FNVS#SNNTSR | 24.44; 9.34 | 4 | −1.424 | |
| TOD6 | |||||
| 300;304 | NSHS#VISS#R | 37.54; 9.34 | 1 | −3.938 | |
| 298;304 | NS#HSVIS#SR | 13.38; 9.34 | 1 | −3.484 | |
| 318;329 | RSS#FNSHAPTEPIS#R | 0; 12.43 | 1 | −2.103 | |
| 298 | NS#HSVIS#SR | 13.38 | 1 | −1.956 | |
| 298;300 | NS#HSVISS#R | 13.40; 37.54 | 1 | −1.382 | |
| STB3 | |||||
| 337;341 | LTATS#EPTS#R | 13.38; 17.25 | 4 | −3.382 | |
| 341 | LTATS#EPTS#R | 17.25 | 2 | −3.144 | |
| 336;341 | LTAT#SEPT#SRR | 24.44; 17.25 | 6 | −2.754 | |
| 336 | LTAT#SEPT#SRR | 24.44 | 1 | −1.767 | |
| IFH1 | |||||
| 1041 | RQS#MVEAAAENLR | 1000 | −2.340 | ||
| ENP1 | |||||
| 5;6 | M*ARAS#S#TK | 4.08; 6.59 | 1 | −1.504 | |
| SCH9 | |||||
| 288 | S#S#SQLDQLNSCSSVTDPSK | 5.75 | 4 | −1.397 |
| Cellular Process . | Site Position . | Sequence . | A-score . | # of peptides . | Log2(Poor/Rich) . |
|---|---|---|---|---|---|
| MEN | |||||
| NET1 | |||||
| 212 | VST#PLAR | 0 | 3 | −4.497 | |
| 259 | ISS#GIDAGK | 24.43 | 6 | −4.409 | |
| 280 | S#ATVDPDK | 30.83 | 2 | −4.343 | |
| 362 | ITS#GM*LK | 24.43 | 3 | −4.259 | |
| 388 | EGPSSPAS#ILPAK | 5.08 | 3 | −3.419 | |
| 270 | SS#IVEEDIVSR | 9.34 | 1 | −3.180 | |
| 447 | S#QSSIADNNGS#PVK | 100.02 | 3 | −3.059 | |
| 301;304 | LLSGT#PIM*STMT#PNR | 4.08 | 3 | −2.740 | |
| 166 | LNNGS#PQSVQPQQQIPSSSGVLR | 15.01 | 2 | −1.640 | |
| 1164 | S#ASAALGK | 30.83 | 2 | −1.331 | |
| 48 | TNM*AQSAGDAS#LQYANLR | 33.66 | 2 | −1.315 | |
| CDC14 | |||||
| 537 | RTTS#AAGGIR | 6.59 | 1 | −2.903 | |
| 494;497 | KNDISS#ASS#SR | 17.01;9.34 | 1 | −1.590 | |
| 429 | SSAVPQTS#PGQPR | 30.83 | 5 | −1.533 | |
| LTE1 | |||||
| 789;793 | VQS#IAIT#PTK | 110.63 | 3 | −2.413 | |
| 718 | ST#IDGLEK | 24.44 | 1 | −2.220 | |
| 779 | QAVVRPAS#GR | 1000 | 1 | −1.857 | |
| 799 | ELS#IVDPEQNK | 1000 | 2 | −1.481 | |
| CDC15 | |||||
| 940 | VSSVT#AAIGSS#PTK | 2.81 | 1 | −1.668 | |
| BFA1 | |||||
| 317 | HCS#NQNVQLNGPAK | 1000 | 1 | −1.614 | |
| NUD1 | |||||
| 352 | APS#ILDK | 1000 | 1 | −1.469 | |
| TORC2 Signaling | |||||
| AVO2 | |||||
| 305 | VNS#INVK | 1000 | 1 | −3.872 | |
| 273 | SS#ITNPVFNPR | 17.01 | 2 | −2.293 | |
| 330;333 | HSAT#PTS#PHNNIALINR | 4.08;6.59 | 1 | −2.061 | |
| 310 | T#PVGVS#PK | 1000 | 1 | −1.432 | |
| 310;315 | T#PVGVS#PK | 1000;1000 | 2 | −1.387 | |
| TAP42 | |||||
| 251;260 | ESNDDDS#TGFT#DK | 85.26;13.38 | 1 | −3.872 | |
| GIN4 | |||||
| 471 | RAS#VINVEK | 1000 | 3 | −3.100 | |
| 382;389 | RQS#ISSVS#VSPSK | 20.17 | 1 | −2.569 | |
| 805 | HFS#ESNK | 30.83 | 2 | −2.338 | |
| 639 | SIS#APM*ENEEK | 0 | 1 | −1.648 | |
| 384 | RQS#IS#SVSVSPSK | 13.21 | 1 | −1.594 | |
| YPK1 | |||||
| 57 | GT#INPSNSSVVPVR | 59.30 | 5 | −2.807 | |
| 57;64 | GT#INPS#NSSVVPVR | 59.30;17.01 | 4 | −2.017 | |
| HSL1 | |||||
| 899 | NIS#QPVNSK | 9.30 | 1 | −2.790 | |
| 1210 | ETT#EEILSK | 9.34 | 2 | −2.082 | |
| 641 | AIHAS#PSTK | 33.66 | 1 | −1.893 | |
| 629;631;632 | SPS#RY#S#LSR | 30.83;24.24;17.01 | 1 | −1.848 | |
| BIT61 | |||||
| 164 | AS#GFFNR | 1000 | 1 | −2.721 | |
| TSC11 | |||||
| 19 | S#VTNTTPLLTPR | 48.87 | 1 | −2.372 | |
| 24;28 | SVTNT#TPLLT#PR | 9.34;65.44 | 1 | −2.176 | |
| 50;52 | NITSSS#PS#TITNESSK | 24.43;9.34 | 1 | −1.936 | |
| 251 | NSQQNLNRNS#TVNSR | 6.59 | 1 | −1.742 | |
| 19;28;32 | S#VTNTTPLLT#PRHS#R | 48.87;65.44;63.08 | 1 | −1.586 | |
| AVO1 | |||||
| 537 | DTVIS#GK | 33.66 | 1 | −2.332 | |
| 543 | EPTS#LTSSNR | 9.34 | 2 | −1.872 | |
| 588 | VSDS#VLHR | 6.59 | 3 | −1.704 | |
| 326 | SHFPTS#QK | 0 | 1 | −1.632 | |
| MSS4 | |||||
| 341 | RSES#ATAEIK | 20.17 | 3 | −2.039 | |
| 238 | HS#QILPM*DDSDVIK | 88.82 | 2 | −2.025 | |
| PKH2 | |||||
| 1005 | THSQS#PSIS#K | 11.01 | 4 | −1.585 | |
| PRK1 | |||||
| 488 | LS#PTIT#SK | 30.83 | 1 | −1.506 | |
| SLM2 | |||||
| 7;11 | NS#ARAS#LDLR | 1000;1000 | 1 | −1.466 | |
| Secretory Pathway | |||||
| SEC16 | |||||
| 1961 | AS#TNQYR | 24.44 | 2 | −3.849 | |
| 759 | GVS#NAS#VGSSASFGAR | 62.66 | 3 | −3.163 | |
| 2144 | TSPSPTGPNPNNSPSPS#S#PISR | 13.38 | 3 | −2.022 | |
| 759;762 | GVS#NAS#VGSSASFGAR | 62.66; 87.26 | 5 | −1.992 | |
| 806 | YAPVS#PTVQQK | 6.59 | 5 | −1.882 | |
| 766;768 | GVSNASVGSS#AS#FGAR | 4.08; 17.01 | 1 | −1.407 | |
| SEC31 | |||||
| 980 | APSS#VSM*VS#PPPLHK | 71.34 | 1 | −1.611 | |
| 988;992 | NS#RVPS#LVATSESPR | 113.18; 99.28 | 6 | −1.514 | |
| 988 | NS#RVPS#LVAT#SESPR | 113.18 | 3 | −1.475 | |
| Ribosome Biogenesis | |||||
| DOT6 | |||||
| 322;326;331 | RSS#FNVS#SNNT#SR | 24.44; 0; 9.34 | 1 | −4.104 | |
| 322 | RSS#FNVSSNNTSR | 24.44 | 2 | −3.133 | |
| 247 | SNS#HSFTNSLNQDPIVR | 11.01 | 2 | −1.687 | |
| 322;331 | RSS#FNVS#SNNTSR | 24.44; 9.34 | 4 | −1.424 | |
| TOD6 | |||||
| 300;304 | NSHS#VISS#R | 37.54; 9.34 | 1 | −3.938 | |
| 298;304 | NS#HSVIS#SR | 13.38; 9.34 | 1 | −3.484 | |
| 318;329 | RSS#FNSHAPTEPIS#R | 0; 12.43 | 1 | −2.103 | |
| 298 | NS#HSVIS#SR | 13.38 | 1 | −1.956 | |
| 298;300 | NS#HSVISS#R | 13.40; 37.54 | 1 | −1.382 | |
| STB3 | |||||
| 337;341 | LTATS#EPTS#R | 13.38; 17.25 | 4 | −3.382 | |
| 341 | LTATS#EPTS#R | 17.25 | 2 | −3.144 | |
| 336;341 | LTAT#SEPT#SRR | 24.44; 17.25 | 6 | −2.754 | |
| 336 | LTAT#SEPT#SRR | 24.44 | 1 | −1.767 | |
| IFH1 | |||||
| 1041 | RQS#MVEAAAENLR | 1000 | −2.340 | ||
| ENP1 | |||||
| 5;6 | M*ARAS#S#TK | 4.08; 6.59 | 1 | −1.504 | |
| SCH9 | |||||
| 288 | S#S#SQLDQLNSCSSVTDPSK | 5.75 | 4 | −1.397 |
The A-score indicates the likelihood a phosphorylation site is correctly localized within a peptide. A given phosphorylation site is correctly assigned with >95% confidence when the A-score is >13. An A-score of 0 indicates that the phosphorylated residue within the peptide sequence cannot be precisely determined. An asterisk (*) represents oxidation of the preceding methionine, an artifact of the sample preparation. A hashtag indicates that the preceding amino acid is likely the relevant phosphorylation site.